RxDoctor Payments Data

Balu Gadhe, MD

Internal Medicine · Loma Linda, CANPI 1740233808

Payments from drug & device makers

$1,380in general payments, 2019–2025

Across 60 payments — averaging $23.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$283
  • Bayer$144
  • Novo Nordisk$136
  • Teva Pharmaceuticals USA, Inc.$106
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$98
  • Otsuka America Pharmaceutical, Inc.$76
  • plus $537 from 15 others

What the payments were for

  • Food & beverage$1,380100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,380 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$18,479
Medicare patients
65
Services billed
173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$87,351
JardianceEmpagliflozin99$77,901
TrulicityDulaglutide49$51,934
EliquisApixaban62$38,867
MounjaroTirzepatide18$24,668
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr32$15,500
Spiriva HandihalerTiotropium Bromide20$10,238
MyrbetriqMirabegron16$8,686
Atorvastatin Calcium683$8,315
JanuviaSitagliptin Phosphate13$8,208
Lantus SolostarInsulin Glargine,hum.Rec.Anlog57$6,494
XareltoRivaroxaban11$6,372
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,645
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate24$5,396
Fluticasone-SalmeterolFluticasone Propion/Salmeterol38$5,356

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$136$87,35176 claims
Lilly USA, LLCTrulicity, Mounjaro$64$76,60267 claims
PfizerEliquis$53$38,86762 claims
GSKAnoro Ellipta$15$15,50032 claims
MerckJanuvia$62$8,20813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Loma Linda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →